MSA Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.75M Buy
6,248
+3,748
+150% +$3.8M 1.73% 11
2025
Q4
$2.69M Hold
2,500
0.67% 16
2025
Q3
$1.91M Hold
2,500
0.48% 16
2025
Q2
$1.95M Hold
2,500
0.49% 15
2025
Q1
$2.06M Buy
2,500
+1,700
+213% +$1.41M 0.53% 14
2024
Q4
$618K Hold
800
0.15% 20
2024
Q3
$709K Hold
800
0.18% 18
2024
Q2
$724K Hold
800
0.21% 18
2024
Q1
$622K Hold
800
0.19% 19
2023
Q4
$466K Buy
+800
New +$467K 0.16% 18

Other funds holding LLY

MSA Advisors's LLY Position: Q1 2026 in Review

MSA Advisors increased its Eli Lilly (LLY) stake by 150% in Q1 2026, buying an estimated $3.8M and bringing the position to 6,248 shares worth $5.75M. The position accounts for 1.73% of the portfolio, ranked #11.

MSA Advisors first reported a position in LLY in Q4 2023 and has held it in 10 quarters since. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • MSA Advisors held 6,248 shares of Eli Lilly worth $5.75M as of Q1 2026.
  • MSA Advisors bought 3,748 Eli Lilly shares in Q1 2026, an estimated $3.8M.
  • Eli Lilly made up 1.73% of MSA Advisors's portfolio in Q1 2026, its #11 holding.
  • MSA Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 10 quarters since.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on MSA Advisors's 13F filing for Q1 2026, filed 18 May 2026.